ProterixBio Announces Commercial Offering of Quantitative Soluble ST2 Assay
Billerica, MA, February 8, 2023: ProterixBio, Inc. today announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is… Read more »
ProterixBio receives Clinical Laboratory Permit from New York State
Billerica, MA, November 17, 2021: ProterixBio, Inc. (CLIA: 22D2189261) today announced it has received a Clinical Laboratory Permit from New York State Department of Health. This permit enables ProterixBio to now perform certain laboratory procedures on specimens accepted from New York State. Together with other accreditations obtained by ProterixBio the company is now licensed to… Read more »
ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital
Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint venture of Harvard University, Massachusetts… Read more »